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Abstract: Malignant solitary fibrous tumor (MSFT) of the pleura is
a rare neoplasm, with unpredictable biologic behavior and a low
sensitivity to chemotherapy. To the authors’ knowledge, no other
effective medical treatment is available for this disease. Imatinib
mesylate is a tyrosine kinase inhibitor targeting the platelet-derived
growth factor (PDGFR- and PDGFR-), the BCR-ABL, and c-KIT
receptors. We report the first evidence of the activity of imatinib in
a symptomatic patient with a chemo- and radio-resistant advanced
MSFT, who obtained a 21-months lasting major clinical benefit with
a consistent reduction in tumor metabolism. Immunostaining of
tumor cells demonstrated the positivity for PDGFR- and PDGFR-
and the absence of c-KIT over-expression, in the absence of c-KIT
and PDGRFR mutations; all the cells strongly and diffusely ex-
pressed the ligand PDGF A in the cytoplasm. This profile suggests
that the observed tumor response was mediated through the inhibi-
tion of the tyrosine kinase activity of PDGFR. Treatment with
imatinib should be considered for patients with recurrent or unre-
sectable MSFTs with PDGFR expression.
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Malignant solitary fibrous tumor (MSFT) of the pleura isa very rare neoplasm, with unpredictable biologic be-
havior. The standard treatment for MSFT is surgery, but
complete surgical resection may be insufficient for cure.
Although anecdotic tumor responses were observed,1 MSFT
are not reported to be sensitive to chemotherapy and, to the
authors’ knowledge, no other effective medical treatment is
available for unresectable disease.2,3 Imatinib mesylate
(Glivec) is a highly selective inhibitor of some tyrosine
kinases, mainly BCR-ABL, platelet-derived growth factor
receptors (PDGFR- and PDGFR-) and c-KIT. The inhibi-
tion of BCR-ABL and KIT mediates its potent efficacy in
CML and GIST, whereas antitumor activity in dermatofibro-
sarcoma protuberans, aggressive fibromatosis, and chordoma
seems to be mediated by the PDGFR, likely via inhibition of
the receptor and consequently of its autocrine pathway.4–9
The PDGFR- gene can harbor constitutive activating muta-
tions in exon 12 and 18, which are very similar to the amino
acidic sequence of c-KIT and seems to predict imatinib
antitumor activity in GIST.10,11
We report here the first evidence of imatinib mesylate
activity in a patient with a chemo- and radio-resistant ad-
vanced MSFT.
A 38-year-old woman was diagnosed with MSFT (Fig-
ure 1) of the pleura and underwent a left pneumonectomy in
1995. A local recurrence developed after 7 years and was
treated with a debulking surgery.
The residual tumor grew continuously and in 2004,
because of a worsening cough and dyspnea, the patient was
treated with 2 subsequent tumor endoscopical resections
followed by thoracic radiation therapy (46 grays [Gy]) and
systemic chemotherapy with doxorubicin 60 mg/m2 every 3
weeks for 4 cycles. No tumor response was observed.
In December 2005, a computed tomography (CT) scan
of the thorax, compared with a similar examination per-
formed in July and September 2005, showed disease progres-
sion with diffuse growing pleuro–pulmonary metastases. A
total body 18F-FDG-PET detected a homogenously increased
glucose uptake in the 2 major tumor areas, parasternal and
retrosternal.
In addition, as molecular targets of potential clinical
interest, we measured the total levels of c-KIT (c-KIT,
DAKO, CA), PDGFR- and PDGFR- (NeoMarkers, Fre-
mont, CA), PDGF A (Santa Cruz, CA) and of activated/
phosphorylated PDGFR- (Cell Signaling, Danvers, MA) by
immunohistochemistry (Table 1 and Figure 2).
We selected breast carcinoma, prostate carcinoma as
positive controls for staining, for PDGF A and PDGFR-,
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respectively. Chordoma was used as positive control of stain-
ing for PDGFR- and phospho-PDGFR-.
All the cells strongly and diffusely expressed the ligand
PDGF A in the cytoplasm, suggesting that an autocrine loop
might be involved in the pathogenesis of this tumor (Figure
2B). In addition, PDGFR- (Figure 2C) and PDGFR- (Fig-
ure 2D) were expressed at moderate-to-high levels (in 80%
and 70% of cells, respectively). A mild immunoreactivity for
the ligand and for PDGFR- and PDGFR- was documented
in the stroma surrounding the tumor cells and also in endo-
thelial cells of tumor vascular tree, while no reactivity for
c-KIT was detected (Figure 2E). Phosphorylation of
PDGFR- was not found either in the tumor cells, the stroma
or the endothelial cells (Figure 1F). The tumor was also
analyzed for mutations in c-KIT (exon 11) and PDGFR-
(exon 12, 14, and 18) genes. Genomic DNA (200 ng) from
paraffin-embedded biopsy sections was amplified by PCR
using specific primers and then purified and sequenced in
both directions. We were not able to identify any genomic
mutation of c-KIT and PDGFR- that would result in con-
stitutive activation of the kinase activity, but only a silent
polymorphism at valine 824 (GTC-GTT).
On the assumption that PDGFR might be implicated in
tumor growth and because of the lack of any potentially
effective systemic or local treatment, the patient underwent
treatment with imatinib mesylate after a written informed
consent was provided. The drug, provided free of charge by
Novartis Pharma AG, was given as a single oral dose of 400
mg daily. At the beginning of the treatment, the patient
suffered from a continuous thoracic pain, severe dyspnea and
worsening coughing attacks, causing cough-syncope and
semi-orthopnoea. Symptoms were partially controlled by 20
mg/day slow-release oral morphine and 4 mg/day oral dexa-
methasone.
In the early days after the initiation of therapy, the
patient demonstrated some progressive improvement of
symptoms and after 3 weeks of imatinib mesylate adminis-
tration, both the cough and dyspnea disappeared allowing for
discontinuation of the supportive care.
Baseline staging of the disease was performed using CT
scan and positron emission tomography (PET) scan. Both
FIGURE 1. The tumor was composed of short spindle cells
with haphazard distribution, hypercellular areas, and varying
degrees of keloid-type collagen deposition. Medium-sized
thin-walled blood vessels in a hemangiopericytic growth pat-
tern were also observed (inset, upper left corner). Increased
mitotic activity and coagulative necrosis (inset, lower right cor-
ner) qualified histologically the malignant nature of the tumor.
TABLE 1. Immunohistochemical Analysis
Antibodies
% of
Tumor Cells Intensity Stroma Endothelial Cells
PDGF A 80   
PDGFR alpha 80 /  
PDGFR beta 70 /  
phospo-PDGFR beta    
The evaluation of PDGF receptors and ligands by immunohistochemistry was based
on the distribution of positive cells with cytoplasmic or membrane reactivity. Staining
were evaluated estimating the percentage of tumor cells expressing immunoreactivity of
the markers analyzed (negative for 0% of tumor cells; focal for 0–10%; moderate for
10–50%; good for 50–75%; diffuse for 75%); grading was performed using a
scale of intensity (, , , ), independent of percentage tumor cells.
FIGURE 2. A, Histology of the tumor revealing an haphaz-
ard growth pattern of ovoid and spindle cells separated by a
background of rope-like collagenized stroma, and showing a
typical patternless appearance. B, The tumor diffusely ex-
pressed the ligand PDGF A in the cytoplasm and in the en-
dothelial cells. C, D, Immunoreactivity for PDGFR (C) and
for PDGFR (D) in the tumor cells and in the stroma. E, Im-
munoreactivity for c-KIT was not detected (see the positivity
in an intratumoral mast cell as internal control). F, No reac-
tivity for phospho-PDGFR- was found in the tumor (inset:
positive control from a chordoma). (A, Hematoxylin and Eo-
sin, original magnification 200). (B–F, Immunohistochemis-
try, original magnification 200).
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examinations were repeated periodically during treatment.
Notable effects on both tumor tissue and tumor metabolism
appeared after 2 months of treatment (Figure 3), CT scans
demonstrated distinct signs of tumor liquefaction with an
inhomogeneous contrast enhancement, the areas of lower
density correlating with the areas of lower glucose uptake
within the lesions. The previously increasing tumor size was
stabilized with the treatment. Accordingly, the PET scan
detected a decrease in the glucose uptake that disappeared in
a substantial portion of both the 2 major tumor areas and
became inhomogeneous. Indeed, the maximum standard up-
take (SUV bw max) values decreased in both the target
lesions, from 3.9 and 5.2 g/ml to 2.5 and 3.2 g/ml, respec-
tively (see graphs in Figure 3).
After 8 months of uneventful treatment, due to wors-
ening of dyspnea and increase of tumor metabolism (3.59 and
4.24 g/ml, respectively), the imatinib dose was increased up
to a dose of 800 mg daily, with a renewed clinical benefit
(reduction of dexamethasone).
After 13 months of treatment and because of accumu-
lating side effects of imatinib mesylate, the treatment was
stopped. At the first PET scan evaluation, performed 3
months later, we observed a striking increase of glucose
uptake (6.3 and 7.2 g/ml). Accordingly, the patient had
dyspnea and coughing, and developed dysphagia and signs of
mediastinic syndrome. The reintroduction of imatinib mesy-
late at a dose of 800 mg/day led to a new decrease of glucose
uptake (see graphs in Figure 2) and, again, a reduction in
dyspnea and coughing and a reduction of the jugular turgor as
well. The clinical benefit had lasted for 8 additional months,
with stable CT scan images, and then the patient had a
pericardial progression.
In conclusion, the clinical benefit combined with the
inhibition of tumor growth as evidenced by CT scan, and the
decrease in tumor metabolism, which correlate strikingly
with the administration of the drug, indicate the effectiveness
of imatinib mesylate in this case. This result suggests that
imatinib mesylate may represent a potential treatment for
MSFTs, expressing PDGFR.
Further, the observed tumor molecular profile suggests
that the tumor response could be in fact mediated by PDGFR-
tyrosine kinase inhibition, supporting further investigation of
the role of PDGFR in this rare neoplasm. Treatment with
FIGURE 3. CT-PET scan images representing
the Suv bw max of the 2 main lesions, the
retrosternal (panels A) and the parasternal
(panels B). The corresponding graphs illustrate
the trend of Suv bw max during the whole
treatment. The arrows indicate: 1. start of the
treatment, 2. tumor response to Imatinib 400
mg/day, 3. first disease evaluation after treat-
ment discontinuation, 4. tumor response after
reintroduction of Imatinib 800 mg/day. Note:
the first patient’s radiologic assessment was
performed in an external hospital and it was
not a CT-PET scan image.
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imatinib should be considered for patients with recurrent or
unresectable MSFTs with PDGFR expression.
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